{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T02:15:49Z","timestamp":1789352149805,"version":"build-2803163510"},"reference-count":30,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2010,2,8]],"date-time":"2010-02-08T00:00:00Z","timestamp":1265587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2010,8]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Effective antiretroviral therapy (ART) has transformed the care of people with HIV, but it is important to monitor time trends in indicators of treatment success and antic future changes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We assessed time trends from 2000 to 2007 in several indicators of treatment success in the UK Collaborative HIV Cohort (CHIC) Study, and using national HIV data from the Health Protection Agency (HPA) we developed a model to project future trends.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The proportion of patients on ART with a viral load &lt;50\u2003HIV\u20101\u2003RNA\u2003copies\/mL increased from 62% in 2000 to 84% in 2007, and the proportion of all patients with a CD4 count &lt;200\u2003cells\/\u03bcL decreased from 21% to 10%. During this period, the number of patients who experienced extensive triple class failure (ETCF) rose from 147 (0.9%) to 1771 (3.9%). The number who experienced such ETCF and had a current viral load &gt;50\u2003copies\/mL rose fromz 118 (0.7%) to 857 (1.9%). Projections to 2012 suggest sustained high levels of success, with a continued increase in the number of patients who have failed multiple drugs but a relatively stable number of such patients experiencing viral loads &gt;50\u2003copies\/mL. Numbers of deaths are projected to remain low.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>There have been continued improvements in key indicators of success in patients with HIV from 2000 to 2007. Although the number of patients who have ETCF is projected to rise in the future, the number of such patients with viral loads &gt;50\u2003copies\/mL is not projected to increase up to 2012. New drugs may be needed in future to sustain these positive trends.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2009.00809.x","type":"journal-article","created":{"date-parts":[[2010,2,8]],"date-time":"2010-02-08T20:28:15Z","timestamp":1265660895000},"page":"432-438","source":"Crossref","is-referenced-by-count":30,"title":["Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations<sup>*<\/sup>"],"prefix":"10.1111","volume":"11","author":[{"given":"L","family":"Bansi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Sabin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Delpech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Chadborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Easterbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Gilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Gompels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Leen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Ainsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Orkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Rice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the UK Collaborative HIV Cohort (CHIC) Study and the Health Protection Agency","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,7,2]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03201-2"},{"key":"e_1_2_6_3_2","first-page":"1194","article-title":"Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland","volume":"315","author":"Egger M","year":"1997","journal-title":"prospective multicentre study"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.7.692"},{"key":"e_1_2_6_6_2","first-page":"695","article-title":"Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom","volume":"330","author":"Sabin C","year":"2005","journal-title":"multicentre cohort study"},{"key":"e_1_2_6_7_2","first-page":"291","article-title":"AIDS across Europe, 1994\u201398","volume":"356","author":"Mocroft A","year":"2000","journal-title":"the EuroSIDA study"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn252"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000168976.51843.9f"},{"key":"e_1_2_6_10_2","first-page":"1947","article-title":"Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy","volume":"190","author":"Mocroft A","year":"2004","journal-title":"results from the EuroSIDA study group"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035211"},{"key":"e_1_2_6_12_2","first-page":"1","article-title":"New treatment options for HIV salvage patients","volume":"57","author":"Hughes A","year":"2008","journal-title":"an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2005.00310.x"},{"key":"e_1_2_6_14_2","first-page":"2791","article-title":"Darunavir","volume":"67","author":"Fenton C","year":"2007","journal-title":"in the treatment of HIV-1 infection"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.6.4.427"},{"key":"e_1_2_6_16_2","first-page":"536","article-title":"HIV in the UK 1980\u20132006","volume":"8","author":"Phillips A","year":"2007","journal-title":"reconstruction using a model of HIV infection and the effect of antiretroviral therapy"},{"key":"e_1_2_6_17_2","first-page":"115","article-title":"The creation of a large UK\u2010based multicentre cohort of HIV\u2010infected individuals","volume":"5","author":"UK CHIC SC.","year":"2004","journal-title":"the UK collaborative HIV cohort (UK CHIC) study"},{"key":"e_1_2_6_18_2","unstructured":"SOPHID.2009. Available athttp:\/\/www.hpa.org.uk\/webw\/HPAweb&Page&HPAwebAutoListDate\/Page\/1201094588844?p=1201094588844."},{"key":"e_1_2_6_19_2","first-page":"1443","article-title":"Outcomes from monitoring of patients on antiretroviral therapy in resource\u2010limited settings with viral load, CD4 cell count, or clinical observation alone","volume":"371","author":"Phillips A","year":"2008","journal-title":"a computer simulation model"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2008.00519.x"},{"key":"e_1_2_6_21_2","first-page":"863","article-title":"Clinical progression and virological failure on highly active antiretroviral therapy in HIV\u20101 patients","volume":"353","author":"Ledergerber B","year":"1999","journal-title":"a prospective cohort study"},{"key":"e_1_2_6_22_2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/00002030-199902250-00009","article-title":"Virological response to protease inhibitor therapy in an HIV clinic cohort","volume":"13","author":"Staszewski S","year":"1999","journal-title":"AIDS"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200112070-00006"},{"key":"e_1_2_6_24_2","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1177\/135965350701200606","article-title":"Genotypic drug resistance and long\u2010term mortality in patients with triple\u2010class antiretroviral drug failure","volume":"12","author":"Lohse N","year":"2007","journal-title":"Antivir Ther"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16589-6"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200003303421303"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.300.1.51"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282e9a664"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32801138f7"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.8-3-250"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-985X.2007.00537.x"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2009.00809.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2009.00809.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T22:17:34Z","timestamp":1698617854000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2009.00809.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,2]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["10.1111\/j.1468-1293.2009.00809.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2009.00809.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,2]]}}}